IDH1 and prostate carcinoma: In the TCGA prostate cancer dataset, the prostate tumours with the highest genome-wide levels of DNA hypermethylation carry IDH1 point mutations, and this suggests that perturbations in alpha-ketoglutarate and succinate levels associated with these mutations disrupting methylation status by inhibiting TET enzyme activity and the conversion of methyl- to 5-hydroxymethylcytosine marks (62).